EB treatments | Average disease severity (%)a | Efficacy (%)b |
---|---|---|
CB23-6 | 33.2 ± 3.78 abcdc | 43.4 |
CC72-14 | 42.8 ± 4.25 bcde | 27.1 |
CB82-16 | 44.6 ± 4.30 cde | 24.0 |
CB93-19 | 36.0 ± 2.01 abcde | 38.7 |
CB182-37 | 48.1 ± 5.08 ef | 18.1 |
CC252-49 | 37.1 ± 2.81 abcde | 36.8 |
CC26-50 | 43.9 ± 5.03 cde | 25.2 |
CA281-56 | 37.3 ± 2.86 abcde | 36.5 |
CA282-57 | 42.6 ± 4.70 bcde | 27.4 |
CA291-60 | 37.2 ± 4.36 abcde | 36.6 |
CA292-61 | 32.1 ± 3.80 abc | 45.3 |
CC293-66 | 36.5 ± 3.20 abcde | 37.8 |
CC30-68 | 43.2 ± 3.32 cde | 26.4 |
CA332-73 | 29.2 ± 2.81 a | 50.3 |
CB361-80 | 29.7 ± 2.54 ab | 49.4 |
CB362-81 | 42.7 ± 3.61 bcde | 27.3 |
CC372-83 | 29.3 ± 2.45 a | 50.1 |
CA38-85 | 37.5 ± 4.15 abcde | 36.1 |
CB382-87 | 39.9 ± 3.00 abcde | 32.0 |
CA391-88 | 36.2 ± 1.95 abcde | 38.3 |
CC393-93 | 48.0 ± 6.54 ef | 18.2 |
CB401-95 | 46.1 ± 5.65 de | 21.5 |
CA411-99 | 37.6 ± 2.13 abcde | 35.9 |
CC44-112 | 31.4 ± 3.10 abc | 46.5 |
Control + | 58.7 ± 4.15 f | 0.00 |